dc.contributor.author | Kirby, Michael | |
dc.contributor.author | Schnetzler, G. | |
dc.contributor.author | Zou, K.H. | |
dc.contributor.author | Symonds, T. | |
dc.date.accessioned | 2011-08-16T09:01:07Z | |
dc.date.available | 2011-08-16T09:01:07Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Kirby , M , Schnetzler , G , Zou , K H & Symonds , T 2011 , ' Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom : A retrospective database study ' , International Journal of Clinical Practice , vol. 65 , no. 7 , pp. 797-806 . https://doi.org/10.1111/j.1742-1241.2011.02693.x | |
dc.identifier.issn | 1368-5031 | |
dc.identifier.uri | http://hdl.handle.net/2299/6243 | |
dc.description | The definitive version can be found at : http://onlinelibrary.wiley.com/ Copyright Wiley-Blackwell [Full text of this article is not available in the UHRA] | |
dc.description.abstract | Aim : To determine the rate of newly detected underlying disease in men receiving their first (index) phosphodiesterase type 5 inhibitor (PDE5i) prescription. Methods : This non-interventional, retrospective study used anonymised patient records from UK general practices identified from the THIN database. Records of men aged ≥ 18 years, who received an index PDE5i prescription between January 1999 and June 2008 and with a continuous medical history (≥ 60 months) before the index prescription were included. Primary end-points were the prevalence of underlying disease prior to the index prescription and to establish the detection rate, defined as cumulative incidence of such a diagnosis in the 3 months following the index prescription. Assessments included comparison with age-matched controls, comparison with identical time periods immediately before and 1 year after, index prescription, and changes over time during the study period. Descriptive statistics, analysis of proportions and multivariate logistic regression analysis were used. Results: Among the 24,708 patients receiving a PDE5i, the prevalence of any underlying diagnosis before the index prescription was 70.23%; prevalence of vasculogenic disease was highest (48.20%). The detection rate of any underlying disease was 11.53%, and again highest for vasculogenic disease (4.07%). Compared with an age-matched control population, the additional detection rate of an unknown underlying disease at PDE5i prescription was 45 for hypertension, 61 for hypercholesterolaemia, 38 for diabetes and 5 for hypogonadism per 10,000 men. Conclusion : Only a minority of men with erectile dysfunction have a previously undiagnosed important underlying disease that is uncovered at the time of an initial PDE5i prescription by a GP. | en |
dc.language.iso | eng | |
dc.relation.ispartof | International Journal of Clinical Practice | |
dc.title | Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom : A retrospective database study | en |
dc.contributor.institution | Centre for Postgraduate Medicine | |
dc.contributor.institution | Health & Human Sciences Research Institute | |
dc.contributor.institution | EDS Trial | |
dc.contributor.institution | Patient Experience and Public Involvement | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1111/j.1742-1241.2011.02693.x | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |